Patients receiving a higher dose of PLN-74809 in the Phase 2a INTEGRIS-IPF clinical trial, which is testing the oral treatment candidate for idiopathic pulmonary fibrosis (IPF), are showing positive safety outcomes. That’s according to data from a safety review analysis conducted by the study’s data safety monitoring board (DSMB)…
Focusing on raising awareness of interstitial lung diseases (ILDs), nine organizations, including the Pulmonary Fibrosis Foundation (PFF), are working together to present the second annual ILD Day, taking place Sept. 14. More than 50,000 Americans are diagnosed every year with ILD, a group of lung diseases marked by inflammation…
The Pulmonary Fibrosis Foundation’s PFF Care Center Network (CCN) now includes 74 medical centers in 34 U.S. states, after six more sites specializing in pulmonary fibrosis (PF) diagnosis, treatment, and patient support joined the nationwide program. “Our new PFF Care Center Network sites offer much-needed comprehensive care for…
The Translational Genomics Research Institute (TGen) will use a big-memory technology, called MemVerge Memory Machine Big Memory virtualization software, to accelerate research on the cellular mechanisms underlying idiopathic pulmonary fibrosis (IPF). “MemVerge Memory Machine has quickly resulted in research value for TGen,” Jonathan Jiang, chief operating officer of…
Horizon Therapeutics has launched its #RAREis Representation program aimed at increasing diversity, equity, and inclusion among patients with rare diseases. There are about 400 million people worldwide living with a rare disease; for many of them, access to diagnosis, care, and treatments can be challenging. Accessing better care depends on…
The first lung transplant using LUNGguard, a cold storage device for transporting donor lungs, was performed in a person with idiopathic pulmonary fibrosis (IPF), Paragonix Technologies, the device’s developer, announced. The first device of its kind to be cleared by the FDA, it became commercially available…
For Rare Disease Day this Feb. 28, the Pulmonary Fibrosis Foundation (PFF) wants to raise public awareness of pulmonary fibrosis (PF), its symptoms and the importance of an early diagnosis. “The PFF is committed to providing quality disease education for the PF community,” Joyce S. Lee, senior medical advisor for…
The American Lung Association (ALA) gave a Catalyst Award, worth $100,000 over two years, to a scientist whose study will address the regeneration of damaged lung tissue. Ya-Wen Chen, PhD, an assistant professor of medicine and stem cell biology and regenerative medicine at the University Southern California (USC), will…
Three Lakes Foundation and the Mayo Clinic have partnered to help people be more aware of pulmonary fibrosis (PF) symptoms, and to be diagnosed earlier in the disease process should they have them. The venture’s ultimate goal is a way of making a remote diagnosis possible, so…
Idiopathic pulmonary fibrosis (IPF) negatively affects a person’s health-related quality of life (HRQoL), especially their physical health, a review study suggests. Patients’ age and disease severity also were found to have an impact on HRQoL. The study, “Health-related quality of life of patients with idiopathic pulmonary fibrosis: a…
Get regular updates to your inbox.
